"GHK-Cu" Names Several Different Chemicals. A New Review Says That Is the Safety Question.

Most safety writing about research compounds asks whether a molecule causes harm. This one asks a question that comes first: which molecule?

A review published in Pharmaceutics on 27 August 2026 argues that "GHK-Cu" is not the name of one substance. It is a label currently applied to at least four chemically distinct things, and the differences between them are exactly the differences that determine how a product behaves — including, in the authors' own list, its toxicity.

The four things under one name

GHK is a tripeptide: glycine, L-histidine, L-lysine. GHK-Cu is that peptide coordinated with a copper(II) ion. The review separates, deliberately and explicitly:

• apo-GHK — the peptide with no copper attached
• canonical GHK-Cu — the specific coordinated complex
• GHK-derived copper peptides — related but not identical structures
• non-GHK copper-peptide systems — different peptides carrying copper

Its central criticism of the existing literature is that papers "frequently treat GHK-Cu as a single active ingredient" despite formulation-dependent variation in coordination state, speciation, stability, pharmacokinetics and toxicity. Four different chemicals, one word, and a body of research that often does not say which one it used.

The variable that matters for harm

The review's safety argument turns on a term worth knowing: labile copper.

Copper that is properly coordinated inside the complex behaves one way. Copper that is loose — not bound, or released when the complex breaks down — behaves differently. The authors propose that any serious development programme needs route-specific labile-copper specifications and route-specific safety decision thresholds, which is a technical way of saying that how much free copper a product carries, and where it is applied, is a safety question requiring an actual number.

Then the finding that makes this a safety article rather than a chemistry one. Across the delivery studies the review examined, particle size, encapsulation efficiency and total peptide and copper content are commonly reported — but molar occupancy, labile copper, and whether what is released is intact GHK-Cu, bare peptide or free copper are usually not resolved at all.

So the measurement most relevant to harm is routinely the one not taken.

Why you cannot tell by looking

Separating these species is not trivial. A paper in the Journal of Chromatography A in October 2026, from a group at the Warsaw University of Technology, needed capillary electrophoresis coupled to inductively coupled plasma tandem mass spectrometry to track what happened to liposome-encapsulated GHK-Cu inside cosmetic formulations — separating the species electrophoretically, then detecting copper and phosphorus selectively, with tandem mass spectrometry required just to suppress interference on the phosphorus signal.

That is the instrumentation it takes to answer "what is actually in this, and is it still intact." Nothing about a label, a colour or a price tells you.

What the human evidence looks like once you insist on knowing

The same review applies that standard to the clinical literature, and the result is thin.

It describes historical cosmetic reports as small or incompletely characterised. A 13-participant study following carbon-dioxide laser resurfacing was negative on its objective endpoints. An 18-participant split-face eyebrow study published in 2026 reported positive cosmetic hair outcomes — but, the reviewers note, did not define GHK-Cu speciation or local exposure, so it is not clear what the participants received.

A separate PRISMA-mapped systematic review in Archives of Internal Medicine Research in August screened 1,247 records and retained 64. Its verdict on the human literature: thin and fragmented, most randomised trials small and conducted on facial cosmetic creams. It notes that microneedle-assisted delivery — the route with the most laboratory support behind it for getting GHK-Cu through skin — has never been evaluated in a single registered, adequately powered human randomised controlled trial published in the peer-reviewed literature.

A registered trial is not a result

One line in the Pharmaceutics review deserves quoting for reasons beyond GHK-Cu. Discussing an ongoing phase 2 acute-wound study, the authors write that it remains recruiting, has no efficacy results, and that its registration cannot be used as evidence of clinical translation.

We have our own reason to underline that. On 5 November we published a correction removing a trial-registry citation from an earlier article, because a registry entry is a filing, not a verified study. It is useful to see a peer-reviewed review state the same principle in its own words, about its own field.

What has not been studied

• No published trial has reported outcomes alongside a defined speciation of the material used, so no human result can be attributed to a specific chemical form.
• Labile copper content is not routinely measured or reported in the products this literature studies.
• Long-term human safety for any form of GHK-Cu is uncharacterised.
• Whether apo-GHK and canonical GHK-Cu differ in human effect has not been tested head to head.

What to watch

The review's own conclusion is the right summary: GHK-Cu should be regarded as a promising but unproven cargo rather than a clinically validated regenerative drug. The result that would change that is a controlled human trial that states, in its methods, exactly which of the four substances it administered and how much of its copper was loose. No published trial has done that yet.

Sources

1. Mateescu DM, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics (2026)
2. Najafi N, et al. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res (2026)
3. Ogórek K, et al. Characterization of copper tripeptide-loaded lipid carriers and their stability in complex cosmetic matrices. J Chromatogr A (2026)

Compounds in this article

GHK-Cu